<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="6c542137-1ac8-4d4e-bca2-16ec8827d59e"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use METAXALONE TABLETS safely and effectively. See full prescribing information for METAXALONE TABLETS.  <br/>
      <br/> METAXALONE tablets, for oral use  <br/>
      <br/> Initial U.S. Approval: 1962 </title>
   <effectiveTime value="20250303"/>
   <setId root="8c1e10fe-0330-4bf8-a94d-aeed80f6aef1"/>
   <versionNumber value="6"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="191427277" root="1.3.6.1.4.1.519.1"/>
            <name>Major Pharmaceuticals</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="901ddd79-9314-4501-87be-4be723921f18"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20241023"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0904-6831" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Metaxalone</name>
                        <formCode code="C42998" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Metaxalone</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <asEquivalentEntity classCode="EQUIV">
                           <code code="C64637" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <definingMaterialKind>
                              <code code="55111-650" codeSystem="2.16.840.1.113883.6.69"/>
                           </definingMaterialKind>
                        </asEquivalentEntity>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="800"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="1NMA9J598Y" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METAXALONE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="1NMA9J598Y" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METAXALONE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="8C3Z4148WZ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ALGINIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>COPOVIDONE K25-31</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="FZ989GH94E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE, UNSPECIFIED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C269C4G2ZQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM ALGINATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="30"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0904-6831-04" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20170831"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="50"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0904-6831-06" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20170831"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA207466" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20170831"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48328" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PINK" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48345" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OVAL" xsi:type="CE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="2" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">SG;323</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_2c27dda6-06f0-c6ae-e063-6294a90a8ff2">
               <id root="2d445bf4-1214-42f9-9753-1aeb5920859a"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20240829"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table styleCode="Noautorules" width="100%">
                           <col width="75%"/>
                           <col width="25%"/>
                           <tbody>
                              <tr>
                                 <td valign="top">
                                    <paragraph>Dosage and Administration (             <linkHtml href="#S2">2</linkHtml>)           </paragraph>
                                 </td>
                                 <td align="right" valign="top">
                                    <paragraph>6/2024</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S1">
               <id root="7132befc-90c2-4582-acff-ee65d943a97e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Metaxalone tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults and pediatric patients 13 years of age and older.</paragraph>
               </text>
               <effectiveTime value="20240829"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Metaxalone tablet is a muscle relaxant indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions in adults and pediatric patients 13 years of age and older. (       <linkHtml href="#_RefS1">1</linkHtml>)     </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S2">
               <id root="1b6623c3-3e8f-4455-a243-317073108f67"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>
                     <content styleCode="xmChange">The recommended dosage of metaxalone tablets in adults and pediatric patients 13 years of age and older 800 mg tablet orally three to four times a day      <content styleCode="italics">[see        </content>
                     </content>
                     <content styleCode="italics">
                        <linkHtml href="#_RefS8">Use in Specific Populations (8)</linkHtml>
                        <content styleCode="xmChange">].      </content>
                     </content>
                     <br/>
                     <content styleCode="xmChange">  Metaxalone tablets, 800 mg are not substitutable on a mg to mg basis with Metaxalone Tablets, 640 mg      <content styleCode="italics">[see        </content>
                     </content>
                     <content styleCode="italics">
                        <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>
                        <content styleCode="xmChange">].      </content>
                     </content>
                     <content styleCode="xmChange">When it is appropriate to switch:     </content>
                     <br/>
                  </paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="xmChange">Switch only in patients who have been taking metaxalone tablets, 640 mg on an empty stomach.</content>
                     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="xmChange">Stop metaxalone tablets, 640 mg three times a day and start metaxalone tablets, 800 mg three times a day on an empty stomach, OR stop metaxalone tablets 640 mg four times a day and start metaxalone tablets, 800 mg four times a day on an empty stomach.</content>
                     </item>
                  </list>
                  <paragraph>
                     <content styleCode="xmChange">Do not switch from metaxalone tablets, 640 mg to metaxalone tablets, 800 mg when the patient is taking food during administration.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240829"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Recommended dosage of metaxalone tablets in adults and pediatric patients 13 years of age and older is 800 mg tablet orally three to four times a day. (         <linkHtml href="#S2">2</linkHtml>)       </item>
                           <item>
                              <caption>•</caption>Metaxalone tablets, 800 mg are not substitutable on a mg to mg basis with Metaxalone Tablets, 640 mg. When it is appropriate to switch, see the Full Prescribing Information on switching instructions. (         <linkHtml href="#S2">2</linkHtml>)       </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S3">
               <id root="edead0a3-8dfa-48ca-ba52-0d22f804eeab"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Tablets:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>800 mg: capsule shape scored, pink debossed with ‘SG’ on scored side and ‘323’ on the other.</item>
                  </list>
               </text>
               <effectiveTime value="20240829"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>800 mg: capsule shape scored, pink debossed with ‘SG’ on scored side and ‘323’ on the other.</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S4">
               <id root="d23c3817-c49e-40a3-8a22-ab4434826c9f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Metaxalone tablets are contraindicated in patients with:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>Known hypersensitivity to any component of metaxalone tablets.</item>
                     <item>
                        <caption>•</caption>Known tendency to drug induced, hemolytic, or other anemias.</item>
                     <item>
                        <caption>•</caption>Severe renal or hepatic impairment.</item>
                  </list>
               </text>
               <effectiveTime value="20240829"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>Known hypersensitivity to any components of this product. (         <linkHtml href="#S4">4</linkHtml>)       </item>
                           <item>
                              <caption>•</caption>Known tendency to drug induced, hemolytic, or other anemias. (         <linkHtml href="#S4">4</linkHtml>)       </item>
                           <item>
                              <caption>•</caption>Severe renal or hepatic impairment. (         <linkHtml href="#S4">4</linkHtml>)       </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S5">
               <id root="a0e08c61-61c4-4250-9f2e-80e15014b903"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20240829"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Serotonin Syndrome</content>: Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of metaxalone tablets (within the recommended dosage range) and other serotonergic drugs and with the use of metaxalone tablets as the only serotonergic drug taken at a dosage higher than the recommended dosage. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dosage increases. Discontinue metaxalone tablets if serotonin syndrome is suspected or it occurs. (         <linkHtml href="#S5.1">5.1</linkHtml>,         <linkHtml href="#S7.1">7.1</linkHtml>)       </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="underline">Central Nervous System (CNS) Depression</content>: Metaxalone tablets may impair mental and/or physical abilities required for the performance of hazardous tasks, such as operating machinery or driving a motor vehicle, especially when used with other CNS depressants including alcohol. Follow patients closely for signs and symptoms of respiratory depression and sedation. If concomitant use is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases. (         <linkHtml href="#S5.2">5.2</linkHtml>,         <linkHtml href="#S7.2">7.2</linkHtml>)       </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S5.1">
                     <id root="8ace2352-a013-4e09-8c43-7cc242c3c102"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Serotonin Syndrome</title>
                     <text>
                        <paragraph>Cases of serotonin syndrome, a potentially life-threatening condition, have been reported during concomitant use of metaxalone tablets (within the recommended dosage range) and other serotonergic drugs     <content styleCode="italics">[see       <linkHtml href="#S7">Drug Interactions (7)</linkHtml>]     </content>and with the use of Metaxalone tablets as the only serotonergic drug taken at a dosage higher than the recommended dosage     <content styleCode="italics">[see       <linkHtml href="#S10">Overdosage (10)</linkHtml>].     </content>
                        </paragraph>
                        <paragraph>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination, rigidity), and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). The onset of symptoms generally occurs within several hours to a few days after initiation of a serotonergic drug, but may occur later than that.</paragraph>
                        <paragraph>If concomitant use of metaxalone tablets and another serotoneric drug is warranted, reassess the patient, particularly during treatment initiation and dosage increases. Discontinue metaxalone tablets if serotonin syndrome is suspected or it occurs.</paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
               <component>
                  <section ID="S5.2">
                     <id root="2cbce855-2b75-4538-aa5e-373a0eb27c77"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Central Nervous System Depression</title>
                     <text>
                        <paragraph>Because of its central nervous system (CNS) depressant effects, metaxalone tablets may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle, especially when used with other CNS depressants including alcohol. Geriatric patients may be especially susceptible to CNS depression associated with metaxalone tablets use. When used concomitantly, the sedative effects of metaxalone tablets and other CNS depressants (e.g., alcohol, benzodiazepines, opioids, tricyclic antidepressants) may be additive     <content styleCode="italics">[see       <linkHtml href="#S7">Drug Interactions (7)</linkHtml>].     </content>
                        </paragraph>
                        <paragraph>Follow metaxalone tablets-treated patients closely for signs and symptoms of respiratory depression and sedation. If concomitant use of metaxalone tablets and another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases.</paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S6">
               <id root="e3209ee0-4ee4-46c8-b649-73ce2973c083"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions associated with the use of metaxalone tablets were identified in clinical studies or postmarketing reports. Because some of these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most frequent reactions to metaxalone were:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="underline">CNS</content>: drowsiness, dizziness, headache, and nervousness or "irritability".     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="underline">Digestive</content>: nausea, vomiting, gastrointestinal upset.     </item>
                  </list>
                  <paragraph>Other adverse reactions were:</paragraph>
                  <list listType="unordered">
                     <item>
                        <caption>•</caption>
                        <content styleCode="underline">CNS</content>: cases of serotonin syndrome have been reported during concomitant use of metaxalone tablets (within the recommended dosage range) and other serotonergic drugs and with the use of metaxalone tablets as the only serotonergic drug at a dosage higher than the recommended dosage       <content styleCode="italics">[see         <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>,         <linkHtml href="#S7.1">Drug Interactions (7.1)</linkHtml>and         <linkHtml href="#S10">Overdosage (10)</linkHtml>]       </content>.     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="underline">Hematologic</content>: leukopenia; hemolytic anemia;     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="underline">Hepatobiliary</content>: jaundice;     </item>
                     <item>
                        <caption>•</caption>
                        <content styleCode="underline">Immune System</content>: anaphylaxis, hypersensitivity reaction, rash with or without pruritus.     </item>
                  </list>
               </text>
               <effectiveTime value="20240829"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (incidence &gt;5%) are nausea and vomiting. (       <linkHtml href="#_RefS6">6</linkHtml>)     </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Dr. Reddy’s Laboratories, Inc. at 1-888-375-3784 or FDA at 1-800-FDA-1088 or         <linkHtml href="file:///C:\Users\katharine.detweiler\AppData\Local\Temp\www.fda.gov\medwatch">www.fda.gov/medwatch</linkHtml>.       </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="S7">
               <id root="db00c5dd-4bec-40ee-bef5-8e33bc3800f9"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20240829"/>
               <component>
                  <section ID="S7.1">
                     <id root="298aa8a3-ed37-47c6-b1a6-9bd385cdfed1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.1 Serotonergic Drugs</title>
                     <text>
                        <paragraph>If concomitant use of metaxalone tablets and another serotoneric drug is warranted, carefully observe the patient, particularly during treatment initiation and dosage modification. Discontinue metaxalone tablets if serotonin syndrome is suspected or if it occurs.</paragraph>
                        <paragraph>Serotonin syndrome has resulted from concomitant use of metaxalone tablets (within the recommended dosage range) with other serotonergic drugs     <content styleCode="italics">[see       <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>and       <linkHtml href="#_RefS6">Adverse Reactions (6)</linkHtml>].     </content>
                        </paragraph>
                        <paragraph>Serotonergic drugs include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, opioids (particularly fentanyl, meperidine, and methadone), drugs that affect the serotonergic neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), and drugs that impair metabolism of serotonin (including monoamine oxidase (MAO) inhibitors, both those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.2">
                     <id root="84be251d-d4a5-4fc9-bc5a-e5cea4bc0738"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.2 CNS Depressants</title>
                     <text>
                        <paragraph>If concomitant use of metaxalone tablets and another CNS depressant is warranted, closely monitor for signs of respiratory depression and sedation, particularly during treatment initiation and dosage increases.</paragraph>
                        <paragraph>Due to the additive pharmacologic effect, concomitant use of metaxalone tablets with other CNS depressants may increase the risk of sedation and respiratory depression     <content styleCode="italics">[see       <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].     </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
               <component>
                  <section ID="S7.3">
                     <id root="9a56cbc7-66d8-401e-a6e8-07bb3f2c4f77"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>7.3 Interaction of Metaxalone with Benedict’s Tests</title>
                     <text>
                        <paragraph>False-positive Benedict's tests, due to an unknown reducing substance, have been noted in metaxalone-treated patients. A glucose-specific test will differentiate findings.</paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S8">
               <id root="88003fab-e426-4c07-83a4-71d1c285c85f"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20240829"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Geriatric Use</content>: Metaxalone tablets-treated geriatric patients may be especially susceptible to CNS depression (       <linkHtml href="#S8.5">8.5</linkHtml>)     </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="S8.1">
                     <id root="774ba048-d7c6-48fe-805b-d2a7c7c1a0a9"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no available data on metaxalone use in pregnant patients to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes despite decades of metaxalone use. Reproduction studies in rats have not revealed effects on the fetus due to metaxalone.</paragraph>
                        <paragraph>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.2">
                     <id root="1b5e434b-397d-4321-9519-7b24125f5420"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>There are no data available to evaluate the presence of metaxalone or its metabolite in either human or animal milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for metaxalone and any potential adverse effects on the breastfed infant from metaxalone or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.4">
                     <id root="4b1238ff-5400-432d-9a60-1ac45e3627bf"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Metaxalone tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomforts associated with acute, painful musculoskeletal conditions in pediatric patients 13 years of age and older. The safety and effectiveness of metaxalone tablets in pediatric patients 12 years of age or younger have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.5">
                     <id root="fd958c77-fd36-4ef7-a9a6-de583a448137"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of metaxalone tablets did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients.</paragraph>
                        <paragraph>Geriatric patients may be especially susceptible to CNS depression associated with metaxalone tablets use     <content styleCode="italics">[see       <linkHtml href="#S5.2">Warnings and Precautions (5.2)</linkHtml>].     </content>
                        </paragraph>
                        <paragraph>The recommended metaxalone tablets dosage in patients 65 years of age and older is the same as in younger adult patients. Metaxalone peak plasma concentrations (Cmax) and area under the curve (AUC) were higher in patients 65 years of age and older in the fasted state; however, a clinically significant difference was not observed when metaxolone was administered in the fed state     <content styleCode="italics">[see       <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>].     </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.6">
                     <id root="da681d84-7698-4b6d-a11c-d627a0c77292"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Hepatic Impairment</title>
                     <text>
                        <paragraph>Metaxalone is contraindicated in patients with severe hepatic impairment. Metaxalone tablets should be used with caution and additional follow-up should be considered in patients with mild to moderate hepatic impairment. The effect of hepatic impairment on metaxalone pharmacokinetics is unknown; however, metaxalone undergoes expensive hepatic metabolism     <content styleCode="italics">[see       <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]     </content>.   </paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
               <component>
                  <section ID="S8.7">
                     <id root="e49cd36a-03ea-40f4-871d-34fbabed907d"/>
                     <code code="88828-9" codeSystem="2.16.840.1.113883.6.1" displayName="RENAL IMPAIRMENT SUBSECTION"/>
                     <title>8.7 Renal Impairment</title>
                     <text>
                        <paragraph>Metaxalone is contraindicated in patients with severe renal impairment. Metaxalone tablets should be used with caution and additional follow-up should be considered in patients with mild to moderate renal impairment. The effect of renal impairment on metaxalone pharmacokinetics is unknown; however, metaxalone undergoes renal excretion as unidentified metabolites     <content styleCode="italics">[see       <linkHtml href="#S12.3">Clinical Pharmacology (12.3)</linkHtml>]     </content>.   </paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S10">
               <id root="2baa0866-4b42-4846-90ce-4f8e1ff5e0d4"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Clinical Presentation of Metaxalone Overdose</content>
                  </paragraph>
                  <paragraph>Deaths by deliberate or accidental overdose have occurred with metaxalone, particularly in combination with other CNS depressants (including alcohol). CNS manifestations may include CNS depression, agitation, hallucinations, delusions, seizures, respiratory depression, and coma. Cardiovascular effects may include tachycardia and hypertension; hypotension has also been reported. Serotonin syndrome, leading to muscle rigidity, tremor, and hyperthermia, has been reported     <content styleCode="italics">[see       <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>,       <linkHtml href="#S7.1">Drug Interactions (7.1</linkHtml>,       <linkHtml href="#S7.2">7.2)</linkHtml>]     </content>.   </paragraph>
                  <paragraph>
                     <content styleCode="underline">Treatment of Metaxalone Overdose</content>
                  </paragraph>
                  <paragraph>The standard of treatment is supportive care. Monitor for CNS and respiratory depression and manage airway with oxygen as needed. Gastrointestinal decontamination procedures (including emesis) should generally be avoided because aspiration may result from CNS depression and seizures. Extracorporeal elimination such as hemodialysis or plasmapheresis have no proven clinical benefit.</paragraph>
                  <paragraph>Consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdose management recommendations.</paragraph>
               </text>
               <effectiveTime value="20240829"/>
            </section>
         </component>
         <component>
            <section ID="S11">
               <id root="ac35d0fa-14fe-4a74-bc91-adbcab4bc725"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Metaxalone Tablets, USP contain 800 mg of metaxalone and the following inactive ingredients: alginic acid, corn starch, ferric oxide red, copovidone, magnesium stearate, povidone, pregelatinized starch, sodium alginate. Metaxalone tablet is a muscle relaxant for oral administration.</paragraph>
                  <paragraph>Chemically, metaxalone is 5-[(3,5- dimethylphenoxy) methyl]-2-oxazolidinone. The empirical formula is C     <sub>12</sub>H     <sub>15</sub>NO     <sub>3</sub>, which corresponds to a molecular weight of 221.25. The structural formula is:   </paragraph>
                  <table styleCode="Noautorules" width="100%">
                     <col width="100%"/>
                     <tbody>
                        <tr>
                           <td valign="top">
                              <renderMultiMedia ID="id591" referencedObject="MM1"/>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Metaxalone, USP is a white to almost white, crystalline powder freely soluble in dichloromethane, soluble in methanol, sparingly soluble in ethanol and ethyl acetate, slightly soluble in toluene and isopropanol, insoluble in water and n-hexane.</paragraph>
               </text>
               <effectiveTime value="20240829"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="metaxalone-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="S12">
               <id root="268c6e5b-6b5b-4865-b17d-0542a23fc016"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20240829"/>
               <component>
                  <section ID="S12.1">
                     <id root="665b91c0-9bfa-4f9d-9f9e-ece2c181172b"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Metaxalone’s mechanism of action has not been fully characterized, but may be related to its sedative properties. Metaxalone has no direct action on the contractile mechanism of striated muscle, the motor end plate, or the nerve fiber.</paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.2">
                     <id root="59d10bd4-1c86-46f9-b377-92793744109d"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of metaxalone not been fully characterized.</paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
               <component>
                  <section ID="S12.3">
                     <id root="ba3103e6-5d44-4d7a-9cf7-90cfc61c44a8"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Metaxalone pharmacokinetics were evaluated in two groups of healthy volunteers that received a single oral dose of 800 mg of metaxalone tablets or 400 mg of metaxalone tablets (0.5 times the approved recommended dose). Metaxalone pharmacokinetic parameters are presented below as mean (% CV) unless otherwise specified. Observed metaxalone peak plasma concentrations (C     <sub>max</sub>) and area under the curve (AUC) are shown in Table 1. Doubling the dose of metaxalone tablets from 400 mg (0.5 times the approved recommended dose) to 800 mg resulted in a proportional increase in metaxalone C     <sub>max</sub>and AUC.   </paragraph>
                        <table ID="_Reftable1" width="70%">
                           <caption>Table 1: Metaxalone Exposure after a Single-Dose of Metaxalone Tablets Under Fasting Conditions Dose</caption>
                           <col width="17%"/>
                           <col width="32%"/>
                           <col width="32%"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode="Botrule Toprule " valign="top">
                                    <content styleCode="bold">Dose</content>
                                 </th>
                                 <th align="center" styleCode="Botrule Toprule " valign="top">
                                    <content styleCode="bold">C           <sub>max</sub>
                                       <sup>2</sup>
                                    </content>
                                 </th>
                                 <th align="center" styleCode="Botrule Toprule " valign="top">
                                    <content styleCode="bold">AUC           <sub>∞</sub>
                                       <sup>2</sup>
                                    </content>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>1</sup>0.5 times the approved recommended dose         </td>
                              </tr>
                              <tr>
                                 <td align="left" colspan="3" valign="top">
                                    <sup>2</sup>Mean (% CV)         </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>400 mg           <sup>1</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>983 (53) ng/mL</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>7,479 (51) ng∙h/mL</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>800 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>1,816 (43) ng/mL</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>15,044 (46) ng∙h/mL</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>The absolute bioavailability of metaxalone is not known. Peak plasma metaxalone concentrations occurred at a mean T     <sub>max</sub>of 3.3 hours (1.5 hours to 5 hours) of metaxalone under fasted conditions.   </paragraph>
                        <paragraph>The single-dose pharmacokinetic parameters of metaxalone in two groups of healthy volunteers who received 400 mg or 800 mg of metaxalone tablets are shown in Table 1.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effect of Food:</content>Peak plasma metaxalone concentrations were noted at a mean T     <sub>max</sub>of 4.3 hours (1.5 hours to 12 hours) under fed conditions. The mean T     <sub>max</sub>under fasting and fed conditions was 3.3 hours and 4.3 hours, respectively. Metaxalone exposure was increased and the half-life (t     <sub>1/2</sub>) was decreased following metaxalone tablets administration with a high fat meal as shown in Table 2. The increase in metaxalone exposure coinciding with a reduction in half-life may be attributed to more complete absorption of metaxalone in the presence of a high fat meal.   </paragraph>
                        <table ID="_Reftable2" width="70%">
                           <caption>Table 2: Relative Changes in Metaxalone Exposure, T       <sub>max</sub>, and t       <sub>1/2</sub>Following Metaxalone Tablets Administration with a High Fat Meal Compared to Fasting     </caption>
                           <col width="12%"/>
                           <col width="13%"/>
                           <col width="17%"/>
                           <col width="17%"/>
                           <col width="12%"/>
                           <col width="12%"/>
                           <thead>
                              <tr>
                                 <th align="center" styleCode="Botrule Toprule " valign="top">
                                    <content styleCode="bold">Dose       </content>
                                    <br/>
                                    <content styleCode="bold">  (mg)     </content>
                                 </th>
                                 <th align="center" styleCode="Botrule Toprule " valign="top">
                                    <content styleCode="bold">C           <sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">  (ng/mL)         </content>
                                 </th>
                                 <th align="center" styleCode="Botrule Toprule " valign="top">
                                    <content styleCode="bold">AUC           <sub>0-t</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">  (ng∙h/mL)         </content>
                                 </th>
                                 <th align="center" styleCode="Botrule Toprule " valign="top">
                                    <content styleCode="bold">AUC           <sub>0-INF</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">  (ng∙h/mL)         </content>
                                 </th>
                                 <th align="center" styleCode="Botrule Toprule " valign="top">
                                    <content styleCode="bold">T           <sub>max</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">  (hrs)         </content>
                                 </th>
                                 <th align="center" styleCode="Botrule Toprule " valign="top">
                                    <content styleCode="bold">t           <sub>1/2</sub>
                                    </content>
                                    <br/>
                                    <content styleCode="bold">  (hrs)         </content>
                                 </th>
                              </tr>
                           </thead>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>400 mg           <footnote ID="_RefK1276">0.5 times the approved recommended dose.</footnote>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>↑ 78%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>↑ 24%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>↑ 15%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>↑ 30%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Toprule " valign="top">
                                    <paragraph>↓ 73%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>800 mg</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>↑ 94%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>↑ 46%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>↑ 42%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>↑ 63%</paragraph>
                                 </td>
                                 <td align="center" styleCode="Botrule " valign="top">
                                    <paragraph>↓ 48%</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>Metaxalone apparent volume of distribution is approximately 800 Liters; however, plasma protein binding is unknown.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>Metaxalone mean ± SD terminal t     <sub>1/2</sub>is 9 ± 4.8 hours and apparent clearance is approximately 67 ± 34 L/h under fasted conditions.   </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism:</content>Metaxalone is primarily metabolized by CYP1A2, CYP2D6, CYP2E1, and CYP3A4 and, to a lesser extent, CYP2C8, CYP2C9, and CYP2C19.   </paragraph>
                        <paragraph>
                           <content styleCode="italics">Excretion:</content>Metaxalone is metabolized by the liver and excreted in the urine as unidentified metabolites.   </paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>The effect of renal impairment and hepatic impairment on metaxalone pharmacokinetics is unknown     <content styleCode="italics">[see       <linkHtml href="#S8.6">Use in Specific Populations (8.6</linkHtml>,       <linkHtml href="#S8.7">8.7)</linkHtml>]     </content>.   </paragraph>
                        <paragraph>
                           <content styleCode="italics">Geriatric Patients:</content>The effects of age on the pharmacokinetics of metaxalone were determined following administration of 800 mg of metaxalone tablets under fasted and fed conditions. Age had a significantly greater effect on metaxalone pharmacokinetics under fasted conditions than under fed conditions. Bioavailability under fasted conditions increased with age. Metaxalone bioavailability under fasted and fed conditions in the three groups of healthy volunteers of varying age is shown in Table 3.   </paragraph>
                        <table ID="_Reftable3" width="70%">
                           <caption>Table 3: Metaxalone Pharmacokinetic Parameters under Fasted and Fed Conditions in Three Age Groups Following Oral Administration of 800 mg of Metaxalone Tablets</caption>
                           <col width="20%"/>
                           <col width="10%"/>
                           <col width="10%"/>
                           <col width="10%"/>
                           <col width="10%"/>
                           <col width="10%"/>
                           <col width="10%"/>
                           <thead>
                              <tr>
                                 <th align="left" styleCode="Rrule Botrule Lrule Toprule " valign="top">
                                    <content styleCode="bold">Mean Age in Years       </content>
                                    <br/>
                                    <content styleCode="bold">  (± SD)     </content>
                                 </th>
                                 <th align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="top">
                                    <content styleCode="bold">26 ± 9 Years Old</content>
                                 </th>
                                 <th align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="top">
                                    <content styleCode="bold">39 ± 11 Years Old</content>
                                 </th>
                                 <th align="center" colspan="2" styleCode="Rrule Botrule Toprule " valign="top">
                                    <content styleCode="bold">72 ± 5 Years Old</content>
                                 </th>
                              </tr>
                              <tr>
                                 <th align="left" styleCode="Rrule Lrule Botrule " valign="top">
                                    <content styleCode="bold">Fasted vs. Fed State</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule " valign="top">
                                    <content styleCode="bold">Fasted</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule " valign="top">
                                    <content styleCode="bold">Fed</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule " valign="top">
                                    <content styleCode="bold">Fasted</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule " valign="top">
                                    <content styleCode="bold">Fed</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule " valign="top">
                                    <content styleCode="bold">Fasted</content>
                                 </th>
                                 <th align="center" styleCode="Rrule Botrule " valign="top">
                                    <content styleCode="bold">Fed</content>
                                 </th>
                              </tr>
                           </thead>
                           <tfoot>
                              <tr>
                                 <td align="left" colspan="7" valign="top">
                                    <sup>1</sup>Mean         </td>
                              </tr>
                           </tfoot>
                           <tbody>
                              <tr>
                                 <td styleCode="Rrule Lrule Toprule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">C             <sub>max</sub>
                                       </content>(ng/mL)           <sup>1</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                    <paragraph>1,816 (43)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                    <paragraph>3,510 (41)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                    <paragraph>2,719 (46)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                    <paragraph>2,915 (55)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                    <paragraph>3,168 (43)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Toprule Botrule " valign="top">
                                    <paragraph>3,680 (59)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">T             <sub>max</sub>
                                       </content>(hours)           <sup>1</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>3 (39)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>4.9 (4.8)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>3 (40)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>8.7 (91)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>2.6 (30)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>6.5 (67)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Lrule Botrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">AUC             <sub>0-t</sub>
                                       </content>(ng•h/mL)           <sup>1</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>14,531 (47)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>20,683 (41)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>19,836 (40)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>20,482 (37)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>23,797 (45)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>24,340 (48)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode="Rrule Botrule Lrule " valign="top">
                                    <paragraph>
                                       <content styleCode="bold">AUC             <sub>∞</sub>
                                       </content>(ng•h/mL)           <sup>1</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>15,045 (46)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>20,833 (41)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>20,490 (39)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>20,815 (37)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>24,194 (44)</paragraph>
                                 </td>
                                 <td align="center" styleCode="Rrule Botrule " valign="top">
                                    <paragraph>24,704 (47)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Male and Female Patients:</content>The exposure of metaxalone was significantly higher in females compared to males as evidenced by C     <sub>max</sub>(2,115 ng/mL     <content styleCode="italics">versus</content>1,335 ng/mL) and AUC     <sub>∞</sub>(17,884 ng∙h/mL     <content styleCode="italics">versus</content>10,328 ng∙h/mL) following administration of 800 mg of metaxalone tablets under fasted conditions. The mean half-life was 11.1 hours in females and 7.6 hours in males. The apparent volume of distribution of metaxalone was approximately 22% higher in males than in females.   </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Studies:</content>Metaxalone does not inhibit CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4. Metaxalone does not induce CYP1A2, CYP2B6, and CYP3A4.   </paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S13">
               <id root="241ccc23-dca9-4377-bff2-309a89c7475d"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20240829"/>
               <component>
                  <section ID="S13.1">
                     <id root="ae995f67-d910-4f25-b16d-3cb2fd059e01"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term studies to evaluate the carcinogenic potential of metaxalone have not been conducted. Studies to evaluate the mutagenic potential of metaxalone have not been conducted. No effects on fertility were observed in rats administered metaxalone.</paragraph>
                     </text>
                     <effectiveTime value="20240829"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="S16">
               <id root="84d6a56f-5d42-458c-be6e-18fbdb3f8dff"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Metaxalone Tablets, USP 800 mg are available as pink, capsule shape scored tablet debossed with ‘SG’ on scored side and ‘323’ on the other.</paragraph>
                  <paragraph>Cartons of 30 tablets (10 tablets each blister pack x 3), NDC 0904-6831-04 </paragraph>
                  <paragraph>Cartons of 50 tablets (10 tablets each blister pack x 5), NDC 0904-6831-06</paragraph>
                  <paragraph>Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [See USP Controlled Room Temperature]. Dispense in well-closed, light-resistant containers.</paragraph>
               </text>
               <effectiveTime value="20240829"/>
            </section>
         </component>
         <component>
            <section ID="S17">
               <id root="16268191-b0a1-4f6f-97bf-41db56fc08a6"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Serotonin Syndrome</content>
                  </paragraph>
                  <paragraph>Inform patients that metaxalone tablets could cause a rare but potentially life-threatening condition called serotonin syndrome. Warn patients of the symptoms of serotonin syndrome and to seek medical attention right away if symptoms develop. Instruct patients to inform their healthcare providers if they are taking, or plan to take, serotonergic drugs     <content styleCode="italics">[see       <linkHtml href="#S5.1">Warnings and Precautions (5.1)</linkHtml>and       <linkHtml href="#S7.1">Drugs Interactions (7.1)</linkHtml>]     </content>.   </paragraph>
                  <paragraph>
                     <content styleCode="underline">Central Nervous System Depression</content>
                  </paragraph>
                  <paragraph>Advise patients that metaxalone tablets may impair mental and/or physical abilities required for performance of hazardous tasks, such as operating machinery or driving a motor vehicle, especially when used with alcohol and other CNS depressants     <content styleCode="italics">[see       <linkHtml href="#S7.2">Drug Interactions (7.2)</linkHtml>]     </content>.   </paragraph>
                  <paragraph>Rx Only</paragraph>
                  <paragraph>Manufactured by:    <br/>  ScieGen Pharmaceuticals, Inc.    <br/>  Hauppauge, NY 11788 ,USA  </paragraph>
                  <paragraph>Manufactured for:    <br/>  Dr. Reddy’s Laboratories Inc.    <br/>  Princeton, New Jersey 08540, USA  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Packaged and Distributed by:</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">MAJOR® PHARMACEUTICALS</content>
                  </paragraph>
                  <paragraph>Indianapolis, IN 46268 USA</paragraph>
                  <paragraph>Refer to package label for Distributor's NDC Number</paragraph>
                  <paragraph>Issued: 8/2024</paragraph>
               </text>
               <effectiveTime value="20240829"/>
            </section>
         </component>
         <component>
            <section ID="ID_af4075aa-e036-4c10-a9d3-fe5b32a5b285">
               <id root="8631b840-304d-45af-8d4e-6644d1b62355"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Package/Label Display Panel </title>
               <text>
                  <paragraph>MAJOR®</paragraph>
                  <paragraph>NDC 0904-6831-06</paragraph>
                  <paragraph>Unit Dose</paragraph>
                  <paragraph>
                     <content styleCode="bold">Metaxalone</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Tablets, USP</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">800 mg</content>
                  </paragraph>
                  <paragraph>50 TABLETS (5 x 10)</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia ID="id930243126" referencedObject="C53FFF6D-876C-4130-A447-699E668E0F00"/>
               </text>
               <effectiveTime value="20240829"/>
               <component>
                  <observationMedia ID="C53FFF6D-876C-4130-A447-699E668E0F00">
                     <text>800mg carton label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="2c27dda6-06ef-c6ae-e063-6294a90a8ff2-00.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>